DK3340993T5 - Forbindelse til anvendelse i fremgangsmåder til behandling af polycystisk nyresygdom - Google Patents
Forbindelse til anvendelse i fremgangsmåder til behandling af polycystisk nyresygdom Download PDFInfo
- Publication number
- DK3340993T5 DK3340993T5 DK16760627.6T DK16760627T DK3340993T5 DK 3340993 T5 DK3340993 T5 DK 3340993T5 DK 16760627 T DK16760627 T DK 16760627T DK 3340993 T5 DK3340993 T5 DK 3340993T5
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- methods
- kidney disease
- polycystic kidney
- treating polycystic
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000030761 polycystic kidney disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562210031P | 2015-08-26 | 2015-08-26 | |
| PCT/US2016/048603 WO2017035319A1 (en) | 2015-08-26 | 2016-08-25 | Methods for treatment of polycystic kidney disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3340993T3 DK3340993T3 (da) | 2023-08-21 |
| DK3340993T5 true DK3340993T5 (da) | 2024-10-07 |
Family
ID=56855838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16760627.6T DK3340993T5 (da) | 2015-08-26 | 2016-08-25 | Forbindelse til anvendelse i fremgangsmåder til behandling af polycystisk nyresygdom |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10633657B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3340993B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6929269B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20250049446A (cg-RX-API-DMAC7.html) |
| CN (2) | CN108135922A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016312590B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2995996A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3340993T5 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2954151T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL257596B (cg-RX-API-DMAC7.html) |
| MA (1) | MA44836A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018002354A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2742300C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017035319A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102759999B1 (ko) * | 2016-12-05 | 2025-02-03 | 레굴루스 테라퓨틱스 인크 | 다낭성 신장 질환의 치료를 위한 변형된 올리고뉴클레오타이드 |
| EP3548011B1 (en) * | 2016-12-05 | 2023-06-14 | Regulus Therapeutics Inc. | Methods for treatment of polycystic kidney disease |
| WO2020038968A1 (en) | 2018-08-23 | 2020-02-27 | Roche Innovation Center Copenhagen A/S | Microrna-134 biomarker |
| WO2024026354A2 (en) * | 2022-07-27 | 2024-02-01 | The General Hospital Corporation | Methods and compositions for use in treating autosomal recessive polycystic kidney disease (arpkd) |
| AU2024304872A1 (en) * | 2023-06-16 | 2025-12-18 | PYC Therapeutics Limited | Compositions and methods for treatment of kidney disease |
| WO2025110217A1 (ja) * | 2023-11-22 | 2025-05-30 | 国立大学法人東海国立大学機構 | 嚢胞性腎疾患の予防及び／又は治療剤 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005013901A2 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| CA2558020A1 (en) | 2004-03-17 | 2005-09-29 | Novartis Ag | Use of renin inhibitors in therapy |
| WO2007126150A1 (ja) * | 2006-04-27 | 2007-11-08 | National University Corporation Nagoya University | 癌の新規治療用組成物 |
| US20120283411A9 (en) * | 2006-06-29 | 2012-11-08 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| CA2927045A1 (en) | 2006-10-03 | 2008-04-10 | Muthiah Manoharan | Lipid containing formulations |
| US20090105174A1 (en) * | 2007-04-20 | 2009-04-23 | Amgen Inc. | Nucleic acids hybridizable to micro rna and precursors thereof |
| WO2009143403A1 (en) * | 2008-05-23 | 2009-11-26 | Targacept, Inc. | Combination therapy for the management hypertension |
| WO2014082644A1 (en) * | 2012-11-30 | 2014-06-05 | WULFF, Peter, Samuel | Circular rna for inhibition of microrna |
| JP2016534069A (ja) * | 2013-10-24 | 2016-11-04 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | Ｈｄａｃ６阻害剤での多嚢胞性疾患の治療 |
| JP2017511694A (ja) * | 2014-02-12 | 2017-04-27 | トーマス・ジェファーソン・ユニバーシティ | マイクロｒｎａ阻害剤を使用するための組成物および方法 |
| KR102759999B1 (ko) | 2016-12-05 | 2025-02-03 | 레굴루스 테라퓨틱스 인크 | 다낭성 신장 질환의 치료를 위한 변형된 올리고뉴클레오타이드 |
| EP3548011B1 (en) | 2016-12-05 | 2023-06-14 | Regulus Therapeutics Inc. | Methods for treatment of polycystic kidney disease |
-
0
- MA MA044836A patent/MA44836A/fr unknown
-
2016
- 2016-08-25 EP EP16760627.6A patent/EP3340993B1/en active Active
- 2016-08-25 IL IL257596A patent/IL257596B/en unknown
- 2016-08-25 DK DK16760627.6T patent/DK3340993T5/da active
- 2016-08-25 WO PCT/US2016/048603 patent/WO2017035319A1/en not_active Ceased
- 2016-08-25 EP EP23179064.3A patent/EP4268891A3/en not_active Withdrawn
- 2016-08-25 CN CN201680049290.6A patent/CN108135922A/zh active Pending
- 2016-08-25 AU AU2016312590A patent/AU2016312590B2/en active Active
- 2016-08-25 RU RU2018108206A patent/RU2742300C2/ru active
- 2016-08-25 MX MX2018002354A patent/MX2018002354A/es unknown
- 2016-08-25 US US15/753,865 patent/US10633657B2/en active Active
- 2016-08-25 JP JP2018510089A patent/JP6929269B2/ja active Active
- 2016-08-25 ES ES16760627T patent/ES2954151T3/es active Active
- 2016-08-25 KR KR1020257010343A patent/KR20250049446A/ko active Pending
- 2016-08-25 CA CA2995996A patent/CA2995996A1/en active Pending
- 2016-08-25 KR KR1020187007997A patent/KR20180080181A/ko not_active Ceased
- 2016-08-25 CN CN202111177217.6A patent/CN114404440A/zh active Pending
-
2020
- 2020-03-19 US US16/823,904 patent/US11168325B2/en active Active
-
2021
- 2021-10-05 US US17/494,234 patent/US20220025372A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016312590A1 (en) | 2018-03-15 |
| CN114404440A (zh) | 2022-04-29 |
| US10633657B2 (en) | 2020-04-28 |
| EP3340993A1 (en) | 2018-07-04 |
| EP3340993B1 (en) | 2023-06-14 |
| ES2954151T3 (es) | 2023-11-20 |
| RU2018108206A (ru) | 2019-09-27 |
| CN108135922A (zh) | 2018-06-08 |
| MA44836A (fr) | 2018-07-04 |
| US11168325B2 (en) | 2021-11-09 |
| AU2016312590B2 (en) | 2021-12-02 |
| WO2017035319A8 (en) | 2021-03-11 |
| RU2018108206A3 (cg-RX-API-DMAC7.html) | 2020-01-14 |
| IL257596A (en) | 2018-04-30 |
| CA2995996A1 (en) | 2017-03-02 |
| IL257596B (en) | 2022-08-01 |
| EP4268891A3 (en) | 2024-01-24 |
| KR20250049446A (ko) | 2025-04-11 |
| JP6929269B2 (ja) | 2021-09-01 |
| RU2742300C2 (ru) | 2021-02-04 |
| US20220025372A1 (en) | 2022-01-27 |
| DK3340993T3 (da) | 2023-08-21 |
| US20200231971A1 (en) | 2020-07-23 |
| HK1256883A1 (en) | 2019-10-04 |
| WO2017035319A1 (en) | 2017-03-02 |
| US20190153442A1 (en) | 2019-05-23 |
| EP4268891A2 (en) | 2023-11-01 |
| MX2018002354A (es) | 2018-12-10 |
| JP2018528945A (ja) | 2018-10-04 |
| KR20180080181A (ko) | 2018-07-11 |
| NZ740040A (en) | 2024-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3186376T3 (da) | Fremgangsmåder til forbedring af cas9-medieret manipulationseffektivitet | |
| DK3559265T3 (da) | Fremgangsmåde til behandling af polynukleotider | |
| DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
| DK3316703T3 (da) | Fremgangsmåde til forbedring af dyrs ydeevne | |
| DK3110988T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3221359T3 (da) | Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof | |
| DK3366295T3 (da) | Fremgangsmåder til behandling af filoviridae virusinfektioner | |
| DK3180426T3 (da) | Genomredigering ved anvendelse af cas9-nickaser | |
| DK3193929T3 (da) | Behandlingsregimer ved anvendelse af anti-nkg2a-antistoffer | |
| DK3185957T3 (da) | Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis | |
| DK3433266T3 (da) | Fremgangsmåder til behandling af mitokondrieforstyrrelser | |
| DK2988743T3 (da) | Heterocykliske forbindelser, der kan anvendes til behandling af sygdom | |
| DK3359281T3 (da) | Fremgangsmåde til udtrækning af CO2 | |
| DK3456330T3 (da) | Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer | |
| DK3483593T3 (da) | Luminescent-oxygen-channeling-immunoassay ved anvendelse af tre antistoffer og fremgangsmåder til fremstilling og anvendelse deraf | |
| DK3177659T3 (da) | Nitrogenholdige forbindelser egnede til anvendelse ved fremstilling af polyurethaner | |
| PL3512642T3 (pl) | Rozwiązanie bezmłotkowe | |
| DK3350463T3 (da) | Drejeleje | |
| DK3393468T3 (da) | Fremgangsmåder til behandling af en immundefektsygdom | |
| HRP20181549T1 (hr) | Pištolj s blokom za zaključavanje | |
| DK3380086T3 (da) | Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer | |
| DK3324824T3 (da) | Fremgangsmåde til behandling af binokulare dysfunktioner | |
| IL257596A (en) | Methods for treatment of polycystic kidney disease | |
| DK4008329T3 (da) | Isoxazolinforbindelser til anvendelse i behandling af demodicose | |
| DK3373980T3 (da) | Fremgangsmåder til behandling af muskeldystrofi |